OptiNose Cash Flow Conversion Efficiency
OptiNose cash flow conversion efficiency. Based on the latest financial reports, OptiNose (OPTN) has a cash flow conversion efficiency ratio of -0.027x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.67 Million) by net assets ($-61.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of OptiNose (2015–2024)
Cash flow conversion efficiency of OptiNose from 2015 to 2024. This chart illustrates how OptiNose's cash flow conversion efficiency has evolved over time, based on yearly financial data. View OPTN share price today for real-time trading data and today's change.
OptiNose Cash Flow Conversion Ratio Explained
OptiNose cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
OptiNose Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OptiNose ranked by their cash flow conversion efficiency. Also see OPTN company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Indústrias Romi S.A
SA:ROMI3
|
-0.005x |
|
Isiklar Enerji ve Yapi Holding AS
IS:IEYHO
|
-0.116x |
|
First Northwest Bancorp
NASDAQ:FNWB
|
0.009x |
|
Vanachai Group Public Company Limited
BK:VNG
|
0.025x |
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLACF
|
-0.003x |
|
Bansal Wire Industries Ltd
NSE:BANSALWIRE
|
0.104x |
|
Charlton Aria Acquisition Corporation Class A Ordinary Shares
NASDAQ:CHAR
|
-0.003x |
|
Flexopack Société Anonyme Commercial and Industrial Plastics Company
AT:FLEXO
|
0.048x |
Annual Cash Flow Conversion Efficiency for OptiNose (2015–2024)
The table below shows the annual cash flow conversion efficiency of OptiNose from 2015 to 2024. Review OPTN FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-40.36 Million | $-44.89 Million | 1.112x | +369.11% |
| 2023-12-31 | $-86.61 Million | $-20.53 Million | 0.237x | -80.16% |
| 2022-12-31 | $-56.62 Million | $-67.65 Million | 1.195x | -66.19% |
| 2021-12-31 | $-21.77 Million | $-76.94 Million | 3.534x | +127.82% |
| 2020-12-31 | $6.79 Million | $-86.21 Million | -12.700x | -761.19% |
| 2019-12-31 | $61.58 Million | $-90.81 Million | -1.475x | -90.50% |
| 2018-12-31 | $118.61 Million | $-91.82 Million | -0.774x | -235.46% |
| 2017-12-31 | $154.50 Million | $-35.65 Million | -0.231x | +95.92% |
| 2016-12-31 | $-3.84 Million | $21.72 Million | -5.659x | -635.04% |
| 2015-12-31 | $-27.15 Million | $-28.71 Million | 1.058x | -- |
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well … Read more